Summary
- Novavax's RSV program is running on fumes; however, it still has value.
- Novavax's flu program remains unsullied but unloved.
- Deals are in the wind.
- Dilution remains the evil spell that keeps Novavax shares under $1.00.
Novavax (NVAX) has accumulated a hefty group of champions and critics over its last ~30 years as a public company. Having pretty much miffed its latest RSV trial, there are precious few champions willing to plunk down their hard-earned cash for an opportunity to check out how the company fares going forward. Indeed, the most recent Seeking Alpha article featuring Novavax as I write is titled "Novavax: No More Hope".
Since the "no hope" article appeared, Novavax has reported its Q4 2018 earnings. This current article is my effort to report on whether I espied any hope left for Novavax shareholders following its report. This article will support the thesis described in its title.
Let me be clear: I am not advocating hope as a viable investment strategy. However, as regards Novavax the proverb "any port in a storm" applies at the current moment. For shareholders who don't want to dump their stock at todays' price, hope is just such a port.
